Requires drug makers to disclose generic delay deals

File S00488 ("Requires drug makers to disclose generic delay deals") is before the New York Legislature and has not been decided. Latest step (January 28, 2026): REPORTED AND COMMITTED TO FINANCE.

New York file S00488, before the New York Legislature. Still to be decided as of 2026-01-28.

What it does

Transparency requirement on generic drug delay arrangements You gain visibility into whether pharmaceutical companies have made deals to keep generic versions off the market, enabling you and your doctor to understand competitive dynamics affecting your medication costs.

The bigger picture

Potential downward pressure on prescription drug prices By deterring or exposing pay-for-delay settlements (where brand-name makers pay generics to stay out), the law could accelerate generic entry and reduce overall medication costs across the market.

What to watch

Enforcement depends on attorney general capacity and follow-up Disclosure requirements alone do not ban these arrangements or guarantee prosecution; if state and federal attorneys general lack resources to investigate reported deals or challenge them in court, the transparency may not translate into faster generic competition or lower prices.

How they voted

Yes (47)

No (15)

Did not vote / other (1)

Read the official record for S00488

See everything up for a vote · This week in New York · See what we have filed with the clerk